Dishonest media are claiming Trump is ending birth right citizenship. This is not the case.
President Trump’s executive order aims to end birthright citizenship for children born to mothers who are either unlawfully present or in the U.S. on temporary visas, provided the father is neither a U.S. citizen nor a lawful permanent resident.
This means the order affects both children of undocumented immigrants as well as children born to parents legally in the U.S. on temporary visas, such as students or tourists.
His rescinding of the Biden-era $2 drug copay has similarly been misrepresented. The Biden program had not yet gone into effect, and it did not reduce the cost of producing drugs.
Instead, it lowered out-of-pocket expenses for some Americans while increasing the burden on taxpayers and leaving drug prices uncapped for everyone else.
President Trump’s executive order on birthright citizenship is titled “PROTECTING THE MEANING AND VALUE OF AMERICAN CITIZENSHIP.”
The title is apt and aligns perfectly with the principles of Make America Great Again.
Being a U.S. citizen is a special privilege, not an automatic entitlement.
Children born to U.S. citizens are citizens, and immigrants who come to the country legally, navigate an immense number of hurdles, and meet all requirements are granted citizenship.
However, this does not apply to the children of illegal aliens within the United States.
The executive accurately order states, “The Fourteenth Amendment has never been interpreted to extend citizenship universally to everyone born within the United States.
The Fourteenth Amendment has always excluded from birthright citizenship persons who were born in the United States but not ‘subject to the jurisdiction thereof.’”
The Constitution itself begins with the words “We the People of the United States of America,” which underscores that it is a document created by and for the American people, outlining their rights and protections—not those of illegal aliens.
President Trump’s executive order rescinding former President Biden’s initiatives to lower prescription drug costs has been unfairly vilified and misrepresented by the media.
Biden’s 2022 executive order proposed testing models to reduce drug prices under Medicare and Medicaid, including capping copayments for generic medications at $2.
However, these initiatives were still in the developmental stages and had not been fully implemented at the time of rescission. In reality, the program did not yet exist—only a pilot program benefiting a small number of people.
The media, however, has portrayed this as a catastrophe, suggesting that lives will be lost immediately due to rising prescription drug prices.
In truth, for the vast majority of people, their drug prices will remain unchanged.
The rationale behind President Trump’s decision includes concerns about the effectiveness and financial sustainability of these programs.
While the proposed $2 copay would have reduced out-of-pocket expenses for patients, it failed to address the underlying high costs of the drugs themselves.
This is typical of socialist programs—people often mistake a decrease in out-of-pocket expenses for a true reduction in costs. What they fail to realize is that the lower price they pay is only possible because of government subsidies, meaning taxpayers were covering the rest.
This, in turn, required more government spending and money printing, contributing to general inflation.
In addition to government subsidies, the Biden administration sought to lower drug prices by negotiating with pharmaceutical companies.
However, the problem with forcing or negotiating a capped price is that it stifles innovation and discourages investment in new drug development.
It costs billions of dollars to bring a drug to market, so while each individual pill may cost only pennies to produce, the billions spent on research and development are factored into the retail price.
If the government imposes price caps, pharmaceutical companies cannot recoup their investments, leading them to reduce or halt funding for the development of new and improved drugs.
It’s important to note that while the $2 copay initiative was rescinded, other measures to reduce prescription drug costs, such as the $2,000 annual cap on out-of-pocket expenses for Medicare beneficiaries, remain in effect.
Biden’s initiatives failed to address the root issue: the high prices set by pharmaceutical companies. Instead, the government would have absorbed the additional financial burden, resulting in higher taxpayer expenses.
This is typical of programs that attempt to solve social problems by simply giving away free money.
It aligns with Biden’s broader pattern of money-printing and giveaway policies that fueled record inflation.
Ironically, he then attempted to tackle the very inflation he caused by spending nearly half a trillion dollars through the Inflation Reduction Act.
The Trump administration’s stance reflects a preference for market-driven solutions and direct negotiations with pharmaceutical companies to achieve sustainable reductions in drug prices.
An analysis of most of Trump’s policies reveals a consistent preference for market forces and outcomes, which are not only fairer than socialist programs but also have the added benefit of being better for the economy in the long term.
Market-based solutions help reduce government spending while addressing the national debt, creating a more sustainable path forward.
The post Exposing Media Bias: The Truth About Trump’s Birthright Citizenship and Drug Pricing Executive Orders appeared first on The Gateway Pundit.